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epithelial sodium channel (ENaC) by means of interferring RNAs and study the
functional consequences of this action. We have used two different approaches,
1) ENaC silencing on human H441 cells by using shRNAs, and 2) on human
primary bronchial epithelia via siRNAs. For the ﬁrst approach, we have selected
two RNA-mediated silencing targets for each of the three subunits, a, b and g of the
ENaC channel and assembled vectors for the production of shRNAs driven by polII-
dependent U1 promoter. Each construct has been subcloned into the episomal vector
pEPI and tested in bronchial H441 cells. From a screening in H441 cells we have
selected the A2 and B2 cassettes directed against the a and b subunits which yield
up to 70% and 40% reduction of the corresponding ENaC mRNA respectively.
The U1-A2 cassette was cloned in an integrating lentiviral vector, derived from
HIV-1. The transduction with this vector (aA2shRNA-LV) determined 40−50%
down-regulation of a ENaC mRNA in H441 cells and reduced also the amount of
b and g mRNA. aA2shRNA-LV efﬁcacy is being investigated in domes, ﬂuid-ﬁlled
hemicystis which are marker of ENaC localization to the cell membrane and formed
in H441 cells upon dexamethasone stimulation. LV infection of domes resulted in
only 0.6% of transduced cells, however LV efﬁciency rised to 92% when cells were
infected before dome appearance. For the second approach, we transfected pools
of commercial siRNA complementary to each of the three ENaC subunits and
measured the protein activity as the transepithelial short-circuit current on polarized
human bronchial epithelia. We found that sequences complementary to any of the
three subunits reduced the functional expression of ENaC, and that this effect lasted
several days. In conclusion, we believe that reduction of Na+ and water absorption
by using an iRNA approach against ENaC could be of beneﬁt to CF patients.
Work funded by the UE grant 005213 and Centro Regionale Fibrosi Cistica, Lazio,
Italy.
*This Poster has been presented also as Oral Communication, by invitation of
the Scientiﬁc Committee
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Non-mammalian hosts, such as the nematode Caenorhabditis elegans, have recently
gained increasing attention as models for molecular pathogenesis studies. Advan-
tages of non-mammalian hosts include their ease of cultivation and short generation
times, as well as the availability of elaborate genetic, biochemical and cell biological
tools. Distinctive mechanisms of C. elegans killing have been deﬁned; among them
infection by many human pathogens, including Pseudomonas aeruginosa (Pa).
P. aeruginosa plays an important role in chronic lung infections among patients
with CF due to its ability to form bioﬁlm, which enables the bacteria to resist
treatments with antibiotics and which affects the actions of the cells of the immune
system.
The majority of P. aeruginosa virulence factors identiﬁed with C. elegans are also
required for virulence in amoebae, D. discoideum, D. melanogaster, plants and
mice; thus supporting the usefulness of the P. aeruginosa–C .elegans pathogenicity
model. When P. aeruginosa strain PA14 is grown on minimal medium, it slowly
kills C. elegans over the course of several days. This killing, called ‘slow killing’ to
differentiate it from toxin-mediated ‘fast killing’, correlates with the accumulation
of live bacteria within the nematode digestive tract.
We report data on the virulence capability of two different Pa isolates based on the
slow killing of C. elegans. One Pa strain was isolated from a CF patient at ﬁrst
colonisation, the other strain was collected from a chronically colonised patient.
We found a reduction in the virulence of the strain harboured by the chronically
colonised patient as compared with the strain collected at ﬁrst colonisation; this was
observed in all C. elegans strains analyzed, including the AU1 C. elegans strain
which harbours a mutation in the sek-1 gene, encoding a MAP kinase involved in
nematode innate immunity.
The reduction of virulence presumably reﬂects the adaptation to the chronic state in
the lungs of the patients. These results are in agreement with emerging evidences
indicating that the establishment of chronic P. aeruginosa infections in the CF lung
does not depend only on virulence factors.
Understanding the mechanisms of persistence of P. aeruginosa in C. elegans may
lead to the identiﬁcation and development of novel therapeutic targets and strategies
aimed at improving protection toward infections in CF patients.
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Introduction: Intestinal symptoms are frequently observed in patients with Cystic
Fibrosis (CF); pancreas insufﬁciency, however, does not provide a satisfactory ex-
planation for all of them. Some studies have showed chronic intestinal inﬂammation
in CF and Crohn disease is more frequent than in general population.
CAL is a calcium and zincum binding protein, belonging to S100 protein family,
that is released during neutrophil activation or death. Plasma CAL is used as an
inﬂammatory marker, while faecal concentration is used to detect intestinal disease.
As faecal marker, CAL is able to differentiate active inﬂammatory bowel disease
(IBD) from inactive as well from irritable bowel syndrome.
Plasma CAL concentration as a marker of pulmonary inﬂammation was tested in
children with CF and found to be a better index of pulmonary exacerbation than
the traditional indices.
The aim of this study is to validate faecal CAL as a non invasive marker of IBD
in CF patients.
Material and methods: Faecal and serum CAL was measured by enzyme-linked
immunosorbent assay in 20 CF patients (9 female and 11 male, mean 11.8 years,
range 7.5−18) attending at our Center. All patients were evaluated in clinically
stable condition as showed by clinic, Rx and biochemical examination.
Control population: 25 faecal samples from 7 IBD patients (2 females and 5 males
mean age 13 years range 13−19) and 10 faecal samples from 10 healthy subjects
(6 males and 4 females, mean age 11 years).
Results: 9/20 (45%) had high faecal CAL levels (> 200mg/kg.) and 3/9 patients
(33.3%) had CAL value > 300mg/kg; all the patients had normal plasmatic levels
(<1.6mg/kg).
Neither correlation between CAL and FEV1 (r: 0.197 P: 0.419), nor CAL and
steatorrhea (r: −0.313 P: 0.379) was found.
All patients with IBD had high faecal CAL values and endoscopic inﬂammation,
all healthy control had normal faecal CAL values (<25 mk/kg).
In CF patients mean faecal CAL values were higher than in healthy controls but
lower than in IBD patients.
Discussion: About 45% of CF patients tested had high faecal CAL levels, all of
them had no pulmonary exacerbations, supporting the idea that IBD is a frequent
feature in CF, as showed by the high prevalence of CD in CF patients. Our
preliminary data suggest that faecal CAL could be a non invasive marker of IBD in
CF and could be usefull to select patients to undergoing to invasive investigations.
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The respiratory tract of cystic ﬁbrosis (CF) patients provides a selective environment
favouring development and persistence of multiple P. aeruginosa pathogenic vari-
ants, that are not eradicable by any known therapy. P. aeruginosa genetic adaptation
is observed in chronic infections of CF patients in contrast to what it is documented
for acute infections. It is not yet known, whether P. aeruginosa clonal variants differ
in their pathogenic potential. A total of 40 clinical P. aeruginosa isolates from ten
CF patients, which carried unique clonal lineage from the onset of colonization over
4−18 years, were selected. Five P. aeruginosa environmental strains, which represent
the source of acquisition for CF patients, and two laboratory strains PAO1 and PA14
were used. Multiple genotypic analysis of sequential P. aeruginosa isolates which
included PFGE, ATchip and multilocus SNPs showed intraclonal diversity with
genome rearrangements, variations in pathogenic islands and acquisition of pro-
thoadaptive mutations in the muc genes and mutS, muL and uvrD genes of the mis-
match repair system. The largest divergence was observed between the completely
sequenced reference strains PAO1 and PA14, the latter represented in our panel by
three CF isolates. P. aeruginosa virulence of different clonal lineages was tested
for their ability to establish a chronic infection or to induce bacteremia in mice.
P. aeruginosa clonal strains differ signiﬁcantly in their virulence. Overall, P. aerug-
inosa clinical strains isolated after years of colonization increased signiﬁcantly
chronic persistence and reduced the risk of bacteremia when compared to strains iso-
lated at the onset of the infection or to those of environmental origin. Furthermore,
our data showed that P. aeruginosa adaptive traits generated in the CF lung, such as
the hypermutable phenotype, increased chronic persistence only in the presence of
antibiotic treatments. The results suggest that the unique genetic proﬁles of P. aerug-
inosa disease-associated isolates are correlated with different pathogenic potential.
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